PERFORMANCE EVALUATION PROGRAM
DRUG SUSCEPTIBILITY TESTING OF STRAINS OF MYCOBACTERIUM TUBERCULOSIS (MTUBERCULOSIS) and NON-TUBERCULOUS MYCOBACTERIA (NTM)
Instructions
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Public Health Practice Program Office
Atlanta, Georgia 30333
WARNING
The
culture panel provided in this survey consists of viable strains of
Mycobacterium
tuberculosis (M. tuberculosis)
and Non-tuberculous Mycobacteria (NTM); some strains are
drug-resistant. The cultures in the panel should be considered
hazardous and capable of transmitting infection. Testing should
only be done if recommended safety procedures are followed as
described in the Centers for Disease Control and Prevention
Biosafety Manual, 1999 4th Edition, Publication No. CDC-93-8395.
This manual recommends use of Biosafety Level 3 practices when
testing M.
tuberculosis cultures.
Please read all instruction sheets completely before proceeding with any culture evaluation.
Check the contents of your package. It should contain:
A cover letter.
An envelope containing:
a. A Results Form for recording test results and instructions for completing the Results Form Booklet.
b. A Laboratory Information Change Form for recording any changes to your laboratory information from previous forms.
c. A pre-addressed envelope for mailing the completed Results Form Booklet and Laboratory Information Change Form (if applicable) to the Program Coordinator at Contractor to be determined (CTD).
A shipping container with a panel of four (4) labeled “TB Test Cultures” and one (1) labeled “NTM Test Culture”. Only four (4) cultures are provided to laboratories that do not perform NTM testing. The culture tubes are labeled with individual alphabetical identification codes.
NOTE: Perform all susceptibility testing in the same manner as you routinely test M. tuberculosis or NTM isolates in your laboratory.
If the contents of your package are not complete, or if additional cultures are required, please call Coordinator (Name) at CTD at xxx-xxx-xxxx or xxx-xxx-xxxx, immediately.
Using your laboratory password, you may enter your result on-line at
https://www.phppo.cdc.gov/mpep/mtbds/login.aspx
Or, use the enclosed Result Form Booklet. The completed Results Form Booklet must be postmarked and mailed to Contractor to be decided (CTD) no later than Month date, year. Use one method, do not do enter your results on-line and mail. To ensure that your data will be included in the tabulations you may (at your expense) return your Results Form Booklet by overnight courier or fax it to xxx-xxx-xxxx. Please send your Results Form to:
CTD
Attention: Program Coordinator
Address
City, State Zip Code
INSTRUCTIONS FOR COMPLETING THE RESULTS FORM AND THE LABORATORY INFORMATION CHANGE FORM
1. Please verify your laboratory information and make any changes on the enclosed Laboratory Information Change Form.
2. For multiple choice questions beginning on page 4 of the Results Form Booklet, fully blacken the circle to the left of the appropriate answer. Please do not use checks marks () or cross marks (X) within the circles.
3. A colored sheet is included providing a case history on the NTM which the participants may want to use in determining the selection of drugs to be tested. Please refer to the NCCLS Guidelines on Susceptibility Testing of Mycobacteria for further testing methods, drugs and concentrations recommended for NTM.
If you need assistance in completing the forms, please call Program Coordinator of CTD at xxx-xxx-xxxx or xxx-xxx-xxxx.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Centers for Disease Control and Prevention
Public Health Practice Program Office
SUSCEPTIBILITY TESTING OF MYCOBACTERIUM TUBERCULOSIS AND
NON-TUBERCULOUS MYCOBACTERIA
RESULTS FORM
Month 2004
The following terms and abbreviations will be used in this survey:
M. tuberculosis = Mycobacterium tuberculosis
NTM = Non-tuberculous mycobacteria
Conc = Concentration
µg = Microgram
Laboratory Name: Shipping
Address of Laboratory (address to which samples should be sent): Street: City: State/Province: Zip/Postal
Code: Country: Telephone
Number:
Prepared For:
Please indicate changes to
your laboratory information on the enclosed
Laboratory
Information Change Form and
return to: Program
Coordinator CTD Address City,
State Zipcode OR Fax
changes to: (xxx) xxx-xxxx OR E-Mail
changes to: programcoordinator@ctd.com
Please indicate changes to your laboratory information on the
enclosed Laboratory Information Change Form and return to:
Tuberculosis Coordinator
DynCorp Systems & Solutions LLC
6101 Stevenson Ave, suite 514
Alexandria, VA 22304
OR
Fax changes to: (703) 461-2020
OR
E-Mail changes to: tbcoordinator@dyncorp.com
Person Completing Form:
1. Name: ___________________________________________________________
Public
reporting of this collection of information is estimated to average
30 minutes per response, including the time for reviewing
instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing the
collection of information. An agency may not conduct or sponsor,
and a person is not required to respond to a collection of
information unless it displays a currently valid OMB control number.
Send comments regarding this burden estimate or any other aspect of
this collection of information, including suggestions for reducing
this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton
Road NE, MS D-24, Atlanta, Georgia 30333; ATTN: PRA (0920-XXX)
2. Title: ___________________________________________________________
3. Please indicate the primary classification of your laboratory. (Please blacken only one circle.)
Hospital
[e.g., city, county, district, community, state, regional, military, Veterans Administration, Federal government
(other than military), privately-owned, university, HMO/PPO-owned and operated, religious-associated]
Health Department
[e.g., city, county, state, regional, district, national reference laboratory]
Independent (non-hospital-based)
[e.g., commercial, commercial manufacturer of reagents, HMO satellite clinic, reference laboratory (non- government affiliated)]
O ther
[e.g., university-associated research, Federal government research (nonmilitary), privately-funded research]
4. In the last calendar year (January 1 - December 31), how many Mycobacterium tuberculosis isolates (excluding quality control isolates) did your laboratory test for drug susceptibilities? (Please write the number of Mycobacterium tuberculosis isolates your laboratory tested for susceptibility in the boxes below.)
|
|
|
|
|
|
Mycobacterium tuberculosis isolates:
The following questions
pertain to the receiving and testing of the culture panel. In most cases,
blacken the circle corresponding to your response in the circle
provided to the left of the answer. Some questions may require more
than one response; please blacken all that apply. In some cases,
you will be asked to fill in the boxes to the right of the answer
with an appropriate comment or number.
5. On what date was the culture panel received in your laboratory?
|
|
/ |
|
|
/ |
|
|
|
|
Month Day Year
6. What was the condition of the cultures in the panel when they arrived?
( Please blacken only one circle.)
Satisfactory
Broken
Other (please explain): _______________________________
7. Please indicate what level of biosafety practices your mycobacteriological laboratory
follows for M. tb cultures. (Please blacken only one circle.)
Biosafety Level 1
Biosafety Level 2
Biosafety Level 3
Biosafety Level 2 for facilities with Level 3 containment equipment
Do not know
8. What procedure(s) was used in your laboratory to perform drug susceptibility testing on these M. tb cultures in this shipment? (Please blacken all that apply.)
Agar Proportion (Middlebrook medium)
Radiometric (BACTEC)
Lowenstein Jensen (LJ) proportion method
MGIT
Other (please specify): __________________________________________
9a. Indicate the primary M. tb susceptibility test medium used by your laboratory for the cultures in this shipment. (Please blacken only one circle.)
B ACTEC 12B (with or without PZA media)
Middlebrook 7H10
M iddlebrook 7H11
ESP-Myco
MGIT
Other (please specify): __________________________________________
TPEP: «lngTPEPNum»
9b. If you use a rapid test method for susceptibility testing of the anti-tuberculosis drugs, do you purchase the drugs from the manufacturer? (Please blacken only one circle.)
Y es
No
Not Applicable
9c. If you use Middlebrook 7H10 or 7H11 media for any anti-tuberculosis drug susceptibility testing, your media is: (Please blacken all that apply.)
p urchased “commercially-prepared” containing anti-tuberculosis drugs
prepared in-house with disks containing anti-tuberculosis drugs
prepared in-house by reconstituting and adding anti-tuberculosis drugs
Not Applicable
Non-tuberculous mycobacteria
10. Does your laboratory perform on-site susceptibility testing of non-tuberculous mycobacteria? (Please blacken only one circle.)
Yes
N o
Not applicable
11. For the species of NTM that you do not test in-house, do you refer (send out) these to another laboratory for drug susceptibility testing? (Please blacken only one circle.)
Y es
N o
Not applicable
12. What procedure(s) was used in your laboratory to perform drug susceptibility testing on the NTM culture in this shipment? (Please blacken all that apply.)
D o Not Perform
Agar Proportion
BACTEC 460
E-Test
Microtiter
Agar Disk Elution
Kirby Bauer
Lowenstein-Jensen
MGIT
Other (please specify): __________________________________________
TPEP: «lngTPEPNum»
M. tuberculosis/NTM Results Form
13. For each antimicrobial that you use routinely to determine the susceptibility of M. tb and NTM isolates, record a test method, the concentration of the antimicrobial and a result (R=Resistant, S=Susceptible, O=Other). (Please see example 1.) If the isolates in the panel were tested using more than one concentration of an antimicrobial, record those results on lines that correspond to the antimicrobial you are testing (example 1). If you need more lines than are provided for that antimicrobial, please record results in the blank lines provided at the bottom of the result page. Do not cross out an existing antimicrobial and write another drug name over it (example 2).
If you are testing an antimicrobial not listed on the result page, record the entire drug name (no abbreviations), a concentration and a result in the blank lines provided at the bottom of the result page. Please make sure that each result is recorded on a provided line and not written in the margins outside the form. Make a copy of the result page if you do not have enough room on the provided page to record all results.
Other responses related to susceptibility results such as Borderline, Contaminated, No Growth, etc. can be abbreviated and recorded to the right of the "O" selection in the result columns (examples 1 and 3).
1. Following are examples of CORRECTLY reported M. tuberculosis results.
Antimicrobial |
Test Method |
Concentration |
Strain K |
Strain L |
Strain M |
|||||
Isoniazid |
A B C O |
|
|
0 |
. |
1 |
|
R S O |
R S O |
R S O NG |
Isoniazid |
A B C O |
|
|
0 |
. |
2 |
|
R S O |
R S O |
R S O NG |
Isoniazid |
A B C O |
|
|
1 |
. |
0 |
|
R S O |
R S O |
R S O NG |
2. Following are examples of INCORRECTLY reported M. tuberculosis results.
Isoniazid |
A B C O |
1 |
2 |
- |
. |
- |
0 |
R S O |
R S O |
R S O |
|
A B C O |
|
|
|
. |
|
|
R S O |
R S O |
R S O |
3. Following are examples of CORRECTLY reported NTM results.
Rifampin |
A B C D E F O |
|
|
1 |
. |
0 |
|
R S O |
< > = |
|
|
|
. |
|
|
R S O |
Rifampin |
A B C D E F O |
|
|
2 |
. |
0 |
|
R S B |
< > = |
|
|
|
. |
|
|
R S O |
Rifampin |
A B C D E F O |
|
|
|
. |
|
|
R S O |
< > = |
|
|
1 |
. |
5 |
|
R S O |
M
TPEP:
These are the results for M. tuberculosis complex testing. The NTM results (if applicable) will go on the next page. **Please provide the Test Method, the Concentration, and the Test Results for each line reported. |
|||||||||||
13. (Continued) Use the blank lines provided at the end of the form for other drugs or additional concentrations. |
A=Agar Proportion B=BACTEC C=L-J Proportion D=MGIT O=Other: (Choose only one) |
Please list each concentration |
Culture Identification Codes(Fill in ONE letter for each culture) R=Resistant S=Susceptible O=Other Please indicate any other responses in the space providedFor example: B=Borderline, C=Contaminated, NG=No growth |
||||||||
Antimicrobial |
Test Method |
Conc. μg/mL |
P |
Q |
R |
S |
|||||
Isoniazid |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Isoniazid |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Isoniazid |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Isoniazid |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Rifampin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Rifampin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Rifampin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Pyrazinamide |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Pyrazinamide |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Pyrazinamide |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ethambutol |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ethambutol |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ethambutol |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Streptomycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Streptomycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Streptomycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ethionamide |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ethionamide |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Kanamycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Kanamycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Capreomycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Capreomycin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Cycloserine |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Cycloserine |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
p-Aminosalicylic acid |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
p-Aminosalicylic acid |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Amikacin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Amikacin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ofloxacin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ofloxacin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ciprofloxacin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Ciprofloxacin |
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
|
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
|
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
|
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
|
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
|
A B C D O |
|
|
|
|
|
|
R S O |
R S O |
R S O |
R S O |
Note: Please provide the complete drug name when filling in additional spaces.
M
TPEP: |
||||||||||||||||
STRAIN T RESULTS – M. fortuitumThese are the results for NTM testing.**Please provide the Test Method, the Concentration, and the Test Results for each line reported. |
||||||||||||||||
|
METHOD |
CONC. |
RESULT |
FOR MIC TEST RESULTS ONLY |
||||||||||||
13.(Continued) Use the blank lines provided at the end of the form for other drugs or additional concentrations. |
A=Agar Proportion B=BACTEC 460 C=L-J Proportion D=E-Test E=Microtiter F=Disk Elution (macro broth) G=Kirby Bauer H=MGIT O=Other: ________ (Choose only one) |
Please list each Concentration (μg/mL) |
R=Resistant S=Susceptible O=Other Please indicate any other responses in the space provided. |
These spaces are for the MIC test results. Blacken the appropriate sign. |
Please list each Concentration (μg/mL) |
R=Resistant S=Susceptible O=Other Please indicate any other responses in the space provided. |
||||||||||
Clarithromycin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Clarithromycin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Azithromycin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Azithromycin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Rifampin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Rifampin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Rifabutin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Rifabutin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Amikacin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Amikacin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Cefoxitin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Cefoxitin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Imipenem |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Imipenem |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Sulfamethoxazole |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Sulfamethoxazole |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
TMP/SMX(TMP)* |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
TMP/SMX(TMP)* |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Ofloxacin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Ofloxacin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Doxycycline |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Doxycycline |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Minocycline |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Minocycline |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Tobramycin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Ciprofloxacin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Isoniazid |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Ethambutol |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
Streptomycin |
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
|
A B C D E F G H O |
|
|
|
|
|
|
R S O |
< > = |
|
|
|
|
|
|
R S O |
* If you are using TMP/SMX, please provide only the concentration for TMP on the appropriate line.
NOTE: Please provide the complete drug name when filling in additional spaces.
File Type | application/msword |
File Title | PERFORMANCE EVALUATION PROGRAM: DRUG SUSCEPTIBILITY TESTING OF STRAINS OF MYCOBACTERIUM TUBERCULOSIS_RESULTS FORM |
Author | bdm6 |
Last Modified By | snp4 |
File Modified | 2006-11-16 |
File Created | 2006-08-30 |